XYLOCAINE SPRAY SPRAY, METERED DOSE

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

LIDOCAINE

Prieinama:

ASPEN PHARMACARE CANADA INC.

ATC kodas:

N01BB02

INN (Tarptautinis Pavadinimas):

LIDOCAINE

Dozė:

10MG

Vaisto forma:

SPRAY, METERED DOSE

Sudėtis:

LIDOCAINE 10MG

Vartojimo būdas:

TOPICAL

Vienetai pakuotėje:

50ML

Recepto tipas:

Ethical

Gydymo sritis:

LOCAL ANESTHETICS

Produkto santrauka:

Active ingredient group (AIG) number: 0103565007; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2000-05-11

Prekės savybės

© 2019 Aspen Group of companies or its licensor. All rights
reserved._ _
_Page 1 of 19_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
XYLOCAINE SPRAY
®
(lidocaine non-aerosol spray)
10mg/metered dose
Non-Sterile
Topical Anesthetic
Aspen Pharmacare Canada Inc
8-1155 North Service Road West
Oakville, Ontario, L6M 3E3
Date of Initial Approval:
December 31, 1993
Date of Revision:
February 19, 2021
Submission Control No: 241236
Trademarks are owned by or licensed to the Aspen Group of companies.
© 2019 Aspen Group of companies or its licensor. All rights
reserved._ _
_Page 2 of 19_
TABLE OF CONTENTS
TABLE OF CONTENTS
..................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
1
INDICATIONS
......................................................................................................
3
1.1
Pediatrics
.....................................................................................................
3
1.2
Geriatrics
.....................................................................................................
3
2
CONTRAINDICATIONS
.......................................................................................
3
3
DOSAGE AND ADMINISTRATION
.....................................................................
3
3.1
Dosing
Considerations.................................................................................
3
3.2
Recommended Dose and Dosage Adjustment
............................................ 4
3.3
Administration
..............................................................................................
5
4
OVERDOSAGE
....................................................................................................
5
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............. 6
6
WARNINGS AND PRECAUTIONS
......................................................................
7
6.1
Special Populations
......................